Dette må vel ses i sammenheng med Merck og Moderna sin avtale på mRNA biten. Det var heller ikke ubetydelig summer Merck spyttet inn i Moderna. De to BP selskapene har et kjempestort samarbeid og spleiset teknologiene sine, og det er ikke umulig at Pcib er en del av det.
Moderna har holdt til i det skjulte og top-tier til Pcib er skjult, hmm(var kanskje å ta den litt langt)
Tar også med denne som jeg postet for tre dager siden, for sammenhengens skyld:
Moderna sine sider gir en fin innføring i mRNA. At dette tar tid er kanskje ikke så rart. Det satses hardt og lykkes de blir det stort. De har også gjort stor fremskritt med levering. Pcib?
We built Moderna on the guiding premise that if using mRNA as a medicine works for one disease, it should work for many diseases. And, if this is possible – given the right approach and infrastructure – it could meaningfully improve how medicines are discovered, developed and manufactured.
Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the "program” or “app” is our mRNA drug - the unique mRNA sequence that codes for a protein.
We have a dedicated team of several hundred scientists and engineers solely focused on advancing Moderna’s platform technology. They are organized around key disciplines and work in an integrated fashion to advance knowledge surrounding mRNA science and solve for challenges that are unique to mRNA drug development. Some of these disciplines include mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering.
Using mRNA to create medicines is a complex undertaking and requires overcoming novel scientific and technical challenges. We need to get the mRNA into the targeted tissue and cells while evading the immune system. If the immune system is triggered, the resultant response may limit protein production and, thus, limit the therapeutic benefit of mRNA medicines. We also need ribosomes to think the mRNA was produced naturally, so they can accurately read the instructions to produce the right protein. And we need to ensure the cells express enough of the protein to have the desired therapeutic effect.
Our multidisciplinary platform teams work together closely to address these scientific and technical challenges. This intensive cross-functional collaboration has enabled us to advance key aspects of our platform and make significant strides to deliver mRNA medicines for patients.